Background: The entity of crystal nephropathies encompasses a spectrum of different kidney injuries induced by crystal-formed intrinsic minerals, metabolites, and proteins or extrinsic dietary components and drug metabolites. Depending on the localization and dynamics of crystal deposition, the clinical presentation can be acute kidney injury, progressive chronic kidney disease, or renal colic. Summary: The molecular mechanisms involving crystal-induced injury are diverse and remain poorly understood. Type 1 crystal nephropathies arise from crystals in the vascular lumen (cholesterol embolism) or the vascular wall (atherosclerosis) and involve kidney infarcts or chronic ischemia, respectively. Type 2 crystal nephropathies arise from intratubular crystal deposition causing obstruction, interstitial inflammation, and tubular cell injury. NLRP3 inflammasome and necroptosis drive renal necroinflammation in acute settings. Type 3 is represented by crystal and stone formation in the draining urinary tract, i.e., urolithiasis, causing renal colic and chronic obstruction. Key Messages: Dissecting the types of injury is the first step towards a better understanding of the pathophysiology of crystal nephropathies. Crystal-induced acti-vation of the inflammasome and necroptosis, crystal adhesion, crystallization inhibitors, extratubulation, and granulo-ma formation are only a few of certainly many involved pathomechanisms that deserve further studies to eventually form the basis for innovative cures for these diseases.

Keywords:
Acute kidney injury, Chronic kidney disease, Fibrosis, Inflammation, Tubulointerstitial nephritis
1.
Mulay SR, Anders HJ: Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol 2017; 13: 226–240.
2.
Mulay SR, Anders HJ: Crystallopathies. N Engl J Med 2016; 374: 2465–2476.
3.
Venturelli C, Jeannin G, Sottini L, Dallera N, Scolari F: Cholesterol crystal embolism (atheroembolism). Heart Int 2006; 2: 155.
4.
Pilely K, et al: Cholesterol crystals activate the lectin complement pathway via ficolin-2 and mannose-binding lectin: implications for the progression of atherosclerosis. J Immunol 2016; 196: 5064–5074.
5.
Mulay SR, et al: Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nat Commun 2016; 7: 10274.
6.
Honarpisheh M, et al: Phagocytosis of environmental or metabolic crystalline particles induces cytotoxicity by triggering necroptosis across a broad range of particle size and shape. Sci Rep 2017; 7: 15523.
7.
Linkermann A, Stockwell BR, Krautwald S, Anders HJ: Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 2014; 14: 759–767.
8.
Duewell P, et al: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357–1361.
9.
Kiyotake R, et al: Human Mincle binds to cholesterol crystals and triggers innate immune responses. J Biol Chem 2015; 290: 25322–25332.
10.
Corr EM, Cunningham CC, Dunne A: Cholesterol crystals activate Syk and PI3 kinase in human macrophages and dendritic cells. Atherosclerosis 2016; 251: 197–205.
11.
Warren BA, Vales O: Electron microscopy of the sequence of events in the atheroembolic occlusion of cerebral arteries in an animal model. Br J Exp Pathol 1975; 56: 205–215.
12.
Gore I, McCombs HL, Lindquist RL: Observations on the fate of cholesterol emboli. J Atheroscler Res 1964; 4: 527–535.
13.
Doshi M, et al: Paraprotein-related kidney disease: kidney injury from paraproteins – what determines the site of injury? Clin J Am Soc Nephrol 2016; 11: 2288–2294.
14.
Motwani SS, et al: Paraprotein-related kidney disease: glomerular diseases associated with paraproteinemias. Clin J Am Soc Nephrol 2016; 11: 2260–2272.
15.
van Slambrouck CM, Salem F, Meehan SM, Chang A: Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int 2013; 84: 192–197.
16.
Robijn S, Hoppe B, Vervaet BA, D’Haese PC, Verhulst A: Hyperoxaluria: a gut-kidney axis? Kidney Int 2011; 80: 1146–1158.
17.
Sayer JA: Progress in understanding the genetics of calcium-containing nephrolithiasis. J Am Soc Nephrol 2017; 28: 748–759.
18.
Vanholder R, Sever MS, Erek E, Lameire N: Rhabdomyolysis. J Am Soc Nephrol 2000; 11: 1553–1561.
19.
Morfin J, Chin A: Images in clinical medicine. Urinary calcium oxalate crystals in ethylene glycol intoxication. N Engl J Med 2005; 353: e21.
20.
Terlinsky AS, Grochowski J, Geoly KL, Strauch BS, Hefter L: Monohydrate calcium oxalate crystalluria in ethylene glycol poisoning. N Engl J Med 1980; 302: 922.
21.
Hoffmanova I, Kraml P, Andel M: Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others. Expert Opin Drug Saf 2015; 14: 1097–1110.
22.
Hess B: Drug-induced urolithiasis. Curr Opin Urol 1998; 8: 331–334.
23.
Mulay SR, Linkermann A, Anders HJ: Necroinflammation in kidney disease. J Am Soc Nephrol 2016; 27: 27–39.
24.
Mulay SR, Kumar SV, Lech M, Desai J, Anders HJ: How kidney cell death induces renal necroinflammation. Semin Nephrol 2016; 36: 162–173.
25.
Mulay SR, Holderied A, Kumar SV, Anders HJ: Targeting Inflammation in so-called acute kidney injury. Semin Nephrol 2016; 36: 17–30.
26.
McComb S, et al: Cathepsins limit macrophage necroptosis through cleavage of Rip1 kinase. J Immunol 2014; 192: 5671–5678.
27.
Liu W, et al: RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc Natl Acad Sci USA 2018; 115:E1475–E1484.
28.
Martin-Sanchez D, et al: Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J Am Soc Nephrol 2017; 28: 218–229.
29.
Linkermann A, et al: Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA 2014; 111: 16836–16841.
30.
Kumar SV, et al: Neutrophil extracellular trap-related extracellular histones cause vascular necrosis in severe GN. J Am Soc Nephrol 2015; 26: 2399–2413.
31.
Desai J, et al: PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling. Eur J Immunol 2016; 46: 223–229.
32.
Desai J, et al: Particles of different sizes and shapes induce neutrophil necroptosis followed by the release of neutrophil extracellular trap-like chromatin. Sci Rep 2017; 7: 15003.
33.
Mulay SR, et al: Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 2013; 123: 236–246.
34.
Franklin BS, Mangan MS, Latz E: Crystal formation in inflammation. Annu Rev Immunol 2016; 34: 173–202.
35.
Orlowski GM, et al: Frontline science: multiple cathepsins promote inflammasome-independent, particle-induced cell death during NLRP3-dependent IL-1β activation. J Leukoc Biol 2017; 102: 7–17.
36.
Neumann K, et al: Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity 2014; 40: 389–399.
37.
Noda S: On mechanism of urate kidney stone formation. Scan Electron Microsc 1984(Pt 4): 1801–1808.
38.
Vervaet BA, Verhulst A, D’Haese PC, De Broe ME: Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transplant 2009; 24: 2030–2035.
39.
Knauf F, et al: NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 2013; 84: 895–901.
40.
Anders HJ, et al: The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int 2018; 93: 656–669.
41.
Ludwig-Portugall I, et al: An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int 2016; 90: 525–539.
42.
Lorenz G, Darisipudi MN, Anders HJ: Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 2014; 29: 41–48.
43.
Taguchi K, et al: Colony-stimulating factor-1 signaling suppresses renal crystal formation. J Am Soc Nephrol 2014; 25: 1680–1697.
44.
Umekawa T, Chegini N, Khan SR: Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells. Kidney Int 2002; 61: 105–112.
45.
Worcester EM, Coe FL: Clinical practice. Calcium kidney stones. N Engl J Med 2010; 363: 954–963.
46.
Randall A: The origin and growth of renal calculi. Ann Surg 1937; 105: 1009–1027.
47.
Mulay SR, et al: Hyperoxaluria requires TNF receptors to initiate crystal adhesion and kidney stone disease. J Am Soc Nephrol 2017; 28: 761–768.
48.
Roncal-Jimenez C, et al: Heat stress nephropathy from exercise-induced uric acid crystalluria: a perspective on Mesoamerican nephropathy. Am J Kidney Dis 2016; 67: 20–30.
49.
Miller DC, Wolf JS Jr: Acute renal colic. N Engl J Med 2004; 350: 2422–2423; author reply 2422–2423.
50.
Coe FL, Worcester EM, Evan AP: Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol 2016; 12: 519–533.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.